marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-06-2024
BioCryst Pharmaceuticals Cash Flow 2011-2024 | BCRX
Annual Cash Flow BioCryst Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-95.1 M | -162 M | -142 M | -135 M | -89.6 M | -92.6 M | -41.1 M | -53.4 M | -13.1 M | - | -26.5 M | -37.4 M | -32.3 M |
Depreciation & Amortization |
1.66 M | 1.44 M | 777 K | 748 K | 724 K | 770 K | 704 K | 483 K | 180 K | 177 K | 304 K | 628 K | 886 K |
Accounts Payables |
20.9 M | 14.4 M | 27.8 M | 18.7 M | 14 M | 7.77 M | 6.34 M | 4.27 M | 9.31 M | 2.85 M | 4.17 M | 3.97 M | 2.5 M |
Accounts Receivables |
2.3 M | 8.27 M | 1.98 M | 8.24 M | 22.1 M | 4.29 M | 6.12 M | 8.77 M | 6.24 M | - | 2.12 M | 4.56 M | 5.83 M |
Total Inventories |
28.7 M | 27.5 M | 15.8 M | 7.04 M | - | 1.65 M | - | 500 K | 1.61 M | 683 K | - | - | 263 K |
All numbers in USD currency
Quarterly Cash Flow BioCryst Pharmaceuticals
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -53.7 M | - | - | - | -47.5 M | - | -138 M | - | -77.8 M | - | -110 M | - | -61 M | - | -92.6 M | -54.3 M | -23.3 M | - | -79.1 M | -51.5 M | -27 M | - | -68.6 M | -33.5 M | -19.7 M | - | -30.6 M | -18.2 M | -8.53 M | - | -47.6 M | - | - | - | - | - | - | - | - | - | -8.96 M | - | -22 M | -14.1 M | -11.2 M | - | -30.4 M | -18.6 M | -12.2 M | - | -28.3 M | -17.8 M | -14.3 M |
Depreciation & Amortization |
- | 306 K | - | - | - | 405 K | - | 1.04 M | - | 317 K | - | 606 K | - | 178 K | - | 568 K | 401 K | 218 K | - | 539 K | 357 K | 176 K | - | 572 K | 377 K | 186 K | - | 522 K | 344 K | 172 K | - | 311 K | 136 K | 47 K | - | 137 K | 94 K | 45 K | - | 137 K | 97 K | 53 K | - | 247 K | 183 K | 97 K | - | 461 K | 325 K | 168 K | - | 630 K | 445 K | - |
Accounts Payables |
7.79 M | 11.9 M | 20.9 M | 10.6 M | 13.9 M | 6.25 M | 14.4 M | 8.62 M | - | 13.9 M | 27.8 M | 19.7 M | 10.1 M | 13.5 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 14 M | 14 M | 14 M | 14 M | 7.77 M | 7.77 M | 7.77 M | 7.77 M | 6.34 M | 6.34 M | 6.34 M | 6.34 M | 4.27 M | 4.27 M | 4.27 M | 4.27 M | 9.31 M | 9.31 M | 9.31 M | 9.31 M | 2.85 M | 2.85 M | 2.85 M | 2.85 M | 4.17 M | 4.17 M | 4.17 M | 4.17 M | 3.97 M | 3.97 M | 3.97 M | 3.97 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M |
Accounts Receivables |
2.12 M | 3.58 M | 2.3 M | 1.68 M | 2.07 M | 1.09 M | 8.27 M | 3.02 M | - | 1.93 M | 1.98 M | 3.29 M | 6.51 M | 8.5 M | 8.24 M | 8.24 M | 8.24 M | 8.24 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 4.29 M | 4.29 M | 4.29 M | 4.29 M | 6.12 M | 6.12 M | 6.12 M | 6.12 M | 8.77 M | 8.77 M | 8.77 M | 8.77 M | 6.24 M | 6.24 M | 6.24 M | 6.24 M | 3.85 M | 3.85 M | 3.85 M | 3.85 M | 2.12 M | 2.37 M | 2.12 M | 2.12 M | 4.56 M | 4.56 M | 4.56 M | 4.56 M | 5.83 M | 5.83 M | 5.83 M | 5.83 M |
Total Inventories |
4.45 M | 29.8 M | 28.7 M | 29.6 M | 27 M | 27.5 M | 27.5 M | 27 M | - | 16.1 M | 15.8 M | 13.7 M | 9.85 M | 5.11 M | 7.04 M | 7.04 M | 7.04 M | 7.04 M | - | - | - | 600 K | 1.65 M | 1.65 M | 1.65 M | 1.65 M | - | - | 1.3 M | 655 K | 500 K | 500 K | 500 K | 500 K | 1.61 M | 1.61 M | 1.61 M | 1.61 M | 683 K | 683 K | 683 K | 683 K | - | - | - | - | - | 263 K | 263 K | 263 K | 263 K | 263 K | 263 K | 263 K |
All numbers in USD currency